Effects of SC144 on in vivo ovarian tumor.

Slides:

Advertisements

Similar presentations

Fig. 3 Calcitriol (vitamin D3) enhances p27 accumulation in thyroid follicular carcinoma cells in vivo. WRO cells (5 × 106) cells were injected.

Advertisements

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

by Simon F. De Meyer, Alexander S. Savchenko, Michael S

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Antitumor activity of BAY in patient-derived tumor models.

Figure 2S (Supplementary Data)

Functions of myeloid cells.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

TANs mediate obesity-induced tumor progression and aggravated desmoplasia. TANs mediate obesity-induced tumor progression and aggravated desmoplasia. A,

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Activity of MAC-321 (i. v. and p. o

Instigating, noninstigating, and responding human tumor specimens.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Regorafenib inhibits angiogenesis and induces apoptosis.

Socs1 KD tumors exhibit a more T-cell–inflamed phenotype and increased T-cell activation. Socs1 KD tumors exhibit a more T-cell–inflamed phenotype and.

SW fraction induces S phase arrest and apoptosis.

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

PTENP1 sensitizes renal cancer cells to chemotherapy.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

TSA-mediated changes in cell cycle inhibitor proteins.

In vivo thrombosis of tumor vasculature.

Depletion of HDAC2 sensitizes cells to epirubicin-induced apoptosis.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Tumors treated with anti-Flk-1 mAb have increased tumor cell apoptosis, reduced tumor cell proliferation, and increased tumor necrosis. s.c. Tumors treated.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo. EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

GA reduces the growth of Caki-1 tumor xenografts.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

PPP2R2A overexpression rescues the miR-21–induced biological effects in bladder cancer cells. PPP2R2A overexpression rescues the miR-21–induced biological.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

Antitumor effects of celastrol in vitro and in vivo.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Visualization of tumor vasculature using anti-CD31 immunohistochemistry. Micrographs.

Xenograft regrowth studies.

Neutralization of CSF1 and Ad5-HRG treatment.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

SY-1425 induces maturation in RARA-high AML

miR-100 suppresses bladder cancer cell growth in vitro and in vivo.

Circulating leukocytes are undetectable in blood vessels of solid tumors in RIP1-Tag2 mice even after IL-15/IL-15Rα complex treatment. Circulating leukocytes.

CRA inhibits the growth of human tumor xenografts in vivo.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

HMQ1611 inhibited breast tumor growth in mice.

Effect of CDV on human SF7796 xenografts in vivo.

Whole-mount analysis of tumor induced lymphatic sprouting by confocal microscopy. Whole-mount analysis of tumor induced lymphatic sprouting by confocal.

Effect of SPINDLIN1 protein on cancer cell proliferation and invasion.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Effects of ZOL treatment on pulmonary metastases.

GCS-100 selectively kills KRAS-addicted lung tumors.

Both TKI and EZH2i upregulate H3K27me3 targets, and combined treatment potentiates loss of LSCs. A, summary of global mean mRNA expression changes found.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

CD36 expression in tissue adjacent and distal to the tumor.

Curative effect of W+T treatment in vivo.

Presentation transcript:

Effects of SC144 on in vivo ovarian tumor. Effects of SC144 on in vivo ovarian tumor. A, SC144 treatment reduced tumor blood vessels in OVCAR-8 xenograft mice. Top left, tumors excised from i.p. vehicle-treated and SC144-treated mice are shown. Bottom, immunohistochemical staining for CD31. Percentage of positively stained areas was determined by the number of areas of stained microvessels divided by number of nuclei. Bar, SEM. **, P < 0.01. B, SC144 (i.p.) treatment induced extensive areas of necrosis in OVCAR-8 xenograft mice. Three different fields were used for quantification of areas of necrosis. Bar, SEM. ***, P < 0.001. C, immunohistochemical staining of TUNEL and Ki67. Percentage was determined by the number of double-stained cells divided by the number of nuclei. Bar, SEM. **, P < 0.01; ***, P < 0.001. D, SC144 (i.p.) treatment downregulated gp130/Stat3-mediated gene expression in OVCAR-8 tumors from xenograft mice. Shili Xu et al. Mol Cancer Ther 2013;12:937-949 ©2013 by American Association for Cancer Research